Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC

Plain-language summary

This study looks at the effect of adding electroacupuncture to PD-1 inhibitor treatment, compared with sham (placebo) electroacupuncture, in people with advanced non-small cell lung cancer whose general condition is at the ECOG 2 level. It enrolls patients whose cancer is driver-gene-mutation negative (without changes such as EGFR or ALK). It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Kong Fanming

Intervention

Electroacupuncture (EA), Sham electroacupuncture

Start date

11/30/2025

Estimated completion

12/31/2027

Countries

China

Related genes

Locations

• Tianjin, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients diagnosed with stage ⅢB-Ⅳ non-small cell lung cancer (NSCLC) confirmed by pathological or cytological examination;
* Patients with negative driver gene mutations, excluding those harboring EGFR mutations, ALK rearrangements, or other common driver gene alterations as determined by genetic testing or other molecular biological methods;
* An Eastern Cooperative Oncology Group (ECOG) performance status score of 2;
* A programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1%;
* An expected survival time of more than 3 months, as assessed by the clinician based on the patient's overall condition, tumor progression, and response to treatment;
* Patients with good treatment compliance who provided written informed consent, confirming their understanding of and willingness to undergo treatment and follow-up according to the study protocol.

Exclusion Criteria:

* Patients with a history or concurrent diagnosis of other malignant tumors within the past five years;
* Patients with severe organ impairment or serious comorbidities, such as cardiac dysfunction (New York Heart Association \[NYHA\] class Ⅲ-Ⅳ), hepatic or renal insufficiency, as determined by standard clinical examinations including liver and kidney function tests and electrocardiography;
* Patients with untreated central nervous system (CNS) metastases were excluded; eligible patients were required to have stable disease confirmed by imaging after receiving at least one systemic or surgical treatment;
* Patients with psychiatric disorders, including schizophrenia or bipolar disorder, particularly those requiring pharmacologic treatment;
* Patients with a history of multiple drug allergies, an allergic predisposition, or a history of severe allergic reactions such as anaphylactic shock or allergic rash;
* Subjects with active autoimmune or infectious diseases, including but not limited to chronic viral hepatitis, active pulmonary tuberculosis, or other infections or autoimmune disorders deemed by clinicians to potentially affect the study;
* Female patients who were pregnant or lactating.